Tropiturn Trio Rota Capsule combines Ciclesonide 400 mcg, Formoterol 12 mcg, and Tiotropium 18 mcg in a triple-action respiratory therapy designed for chronic asthma and COPD management. This combination delivers the benefits of anti-inflammatory corticosteroid, long-acting β2-agonist, and long-acting anticholinergic bronchodilator in a single formulation.
Ciclesonide provides potent anti-inflammatory action, reducing airway inflammation and hyperresponsiveness. Formoterol relaxes airway smooth muscles as a long-acting bronchodilator, improving airflow and reducing acute exacerbations. Tiotropium adds bronchodilation through muscarinic receptor antagonism, providing prolonged relief and better lung function.
This triple-action capsule is ideal for patients requiring comprehensive management of chronic respiratory conditions, reducing the need for multiple medications while enhancing adherence and therapeutic outcomes.
Belonging to the respiratory care segment, Tropiturn Trio Rota Capsule is in high demand among hospitals, pulmonology clinics, and specialty care centers.
For PCD pharma franchise partners, third-party manufacturers, and exporters, Tropiturn Trio Rota Capsule offers a high-value B2B opportunity. Its combination of three active agents ensures strong market demand and profitability across India.